Checkpoint inhibitors produce durable responses in numerous metastatic cancers, but immune-related adverse events (irAEs) complicate and limit their benefit. IrAEs can affect organ systems idiosyncratically; presentations range from mild and self-limited to fulminant and fatal. The molecular mechanisms underlying irAEs are poorly understood. Here, we report a fatal case of encephalitis arising during antiprogrammed cell death receptor 1 therapy in a patient with metastatic melanoma. Histologic analyses revealed robust T cell infiltration and prominent programmed death ligand 1 expression. We identified 209 reported cases in global pharmacovigilance databases (across multiple cancer types) of encephalitis associated with checkpoint inhibitor regimens, with a 19% fatality rate. We performed further analyses from the index case and two additional cases to shed light on this recurrent and fulminant irAE. Spatial and multi-omic analyses pinpointed activated memory CD4 + T cells as highly enriched in the inflamed, affected region. We identified a highly oligoclonal T cell receptor repertoire, which we localized to activated memory cytotoxic (CD45RO + GZMB + Ki67 + ) CD4 cells. We also identified Epstein-Barr virus-specific T cell receptors and EBV + lymphocytes in the affected region, which we speculate contributed to neural inflammation in the index case. Collectively, the three cases studied here identify CD4 , although highly morbid and even fatal events can occur [4] [5] [6] . Inflamed tissues affected by irAEs are characterized by robust infiltration by T lymphocytes and myeloid-lineage cells [5] [6] [7] [8] . Uncommon irAEs affecting the central nervous system (such as encephalitis), peripheral nervous system (such as Guillain-Barre and peripheral sensory neuropathy) and neuromuscular junction (such as myasthenia gravis) have been described 9 . The molecular basis of irAEs, including neurologic irAEs, remains poorly understood despite these early findings.
Checkpoint inhibitors produce durable responses in numerous metastatic cancers, but immune-related adverse events (irAEs) complicate and limit their benefit. IrAEs can affect organ systems idiosyncratically; presentations range from mild and self-limited to fulminant and fatal. The molecular mechanisms underlying irAEs are poorly understood. Here, we report a fatal case of encephalitis arising during antiprogrammed cell death receptor 1 therapy in a patient with metastatic melanoma. Histologic analyses revealed robust T cell infiltration and prominent programmed death ligand 1 expression. We identified 209 reported cases in global pharmacovigilance databases (across multiple cancer types) of encephalitis associated with checkpoint inhibitor regimens, with a 19% fatality rate. We performed further analyses from the index case and two additional cases to shed light on this recurrent and fulminant irAE. Spatial and multi-omic analyses pinpointed activated memory CD4 + T cells as highly enriched in the inflamed, affected region. We identified a highly oligoclonal T cell receptor repertoire, which we localized to activated memory cytotoxic (CD45RO + GZMB + Ki67 + ) CD4 cells.
We also identified Epstein-Barr virus-specific T cell receptors and EBV
+ lymphocytes in the affected region, which we speculate contributed to neural inflammation in the index case. Collectively, the three cases studied here identify CD4
+

and CD8
+ T cells as culprits of checkpoint inhibitor-associated immune encephalitis.
Monoclonal antibodies blocking key negative regulators of T cell function have transformed the management of numerous cancers 1 . While immune checkpoint inhibitors (ICIs) induce durable responses in some patients, aberrant immune-mediated phenomena, termed irAEs, may be unleashed in an unpredictable fashion 2 . Most irAEs are self-limited or resolve with glucocorticoids 3 , although highly morbid and even fatal events can occur [4] [5] [6] . Inflamed tissues affected by irAEs are characterized by robust infiltration by T lymphocytes and myeloid-lineage cells [5] [6] [7] [8] . Uncommon irAEs affecting the central nervous system (such as encephalitis), peripheral nervous system (such as Guillain-Barre and peripheral sensory neuropathy) and neuromuscular junction (such as myasthenia gravis) have been described 9 . The molecular basis of irAEs, including neurologic irAEs, remains poorly understood despite these early findings.
We performed deep molecular profiling of a case of fulminant anti-programmed cell death receptor 1 (PD-1)-induced encephalitis to provide insight into this severe neurologic irAE. We show that ICI-induced encephalitis occurs across cancer settings and is serious or fatal in many patients. Multi-omic analyses of the index case revealed a clonal CD4 + activated memory cytotoxic T cell population and robust central nervous system (CNS) infiltration by cytotoxic CD4 + and CD8 + T cells.
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A man in his 70s with metastatic melanoma developed meningoencephalitis while receiving pembrolizumab. His prior history was notable for treatment with ipilimumab (complicated by colitis requiring infliximab), brain metastasis treated with resection, and radiation and BRAF and MEK inhibitor therapy (Fig. 1a) . Following progression, he received pembrolizumab, resulting in a near-complete response without toxicity. Approximately 18 months into pembrolizumab therapy, he developed nausea, fevers, confusion and aphasia progressing over 2 d. Brain magnetic resonance imaging (MRI) showed restricted diffusion and enhancement in the basal ganglia and right temporal lobe consistent with inflammatory or herpes simplex virus (HSV) encephalitis ( Fig. 1b ; Supplementary Table 1) . Of note, Epstein-Barr virus (EBV) polymerase chain reaction later returned positive with viral load of 1,200 copies ml -1 and was persistently detected in the blood (1,888-4,321 copies) and across multiple cerebrospinal fluid (CSF) samples; HSV testing was negative. He continued to have neurologic deterioration requiring intubation and mechanical ventilation; MRI showed progressive encephalitis involving both temporal lobes (Fig. 1b) . Methylprednisolone 1 mg kg -1 twice daily was initiated 5 d into the hospitalization, leading to dramatic and rapid clinical improvement.
Two weeks later, he developed recurrent neurologic symptoms while tapering steroids; MRI showed worsening of encephalitis. Subsequent CSF evaluation showed evolution to a lymphocytic predominance (83 nucleated cells, 8% neutrophils, 91% lymphocytes). He then had brief episodes of clinical improvement with high-dose steroids and intravenous immunoglobulin, followed by progressive deterioration of his mental status and motor strength. He died 42 d after symptom onset.
To assess the frequency of encephalitis among patients treated with ICIs, we queried VigiBase (see Methods). We identified 209 reports of encephalitis; the median age was 61 years (range 7−85) and 59% had either melanoma or lung cancer (Table 1) . Overall, 66% of patients received anti-PD-1 monotherapy; 88% of patients had no other concurrent irAEs reported. The median time to symptom onset was 67 d (range 5−456) and 39 patients (19%) died. In contrast with other toxicities (for example myocarditis) 4 , the fatality rate was similar between encephalitis from anti-PD-1 monotherapy versus combined anti-PD-1 and anti-CTLA-4 therapy (20% versus 26%, χ 2 P = 0.50). We next queried 2,501 patients treated with ICIs from four large academic centers to confirm these findings in clinically diagnosed cases of encephalitis and identified 22 cases of meningoencephalitis. These findings (Supplementary Table 2) were and CD8 + T cells; ×20. e, Diffuse PD-L1 positivity staining in cells with macrophage morphology surrounding the region of infarction; ×20. Of particular note, tissues collected and assayed in this study anteceded treatment with steroids and anti-tumor necrosis factor α, which could impact the immunologic status of the patient. Slide staining for each marker was performed 1-3 times in parallel with and compared with positive controls for each marker.
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Nature MediciNe similar to the pharmacovigilance database, with a median onset of 80 d (range 4−684). The most frequent presenting symptom was confusion (50%), followed by headaches (36%), seizures (23%) and fevers (18%). Temporal or occipital lobe enhancement was the most common imaging finding (22%, n = 5). Most patients recovered completely (68%) although five (22%) had persistent neurologic symptoms and two (9%) died; median hospitalization time was 6.5 d (range 2−120). Thus, encephalitis is a rare but recurrent and potentially fatal toxicity of ICIs that occurs across cancer types.
An autopsy of the index case was performed. No evidence of melanoma was observed in the CNS or elsewhere using panmelanoma stains S100, SOX10, melanoma antigen recognized by T cells 1 (MelanA/MART-1) and MITF (data not shown). Analysis of T cell receptors (reported subsequently in this letter) also did not identify any known or likely MelanA/MART-1-specific HLA-A*02:01-restricted T cell receptors (TCRs). Vigorous inflammation, multiple cerebral infarctions with necrosis and sporadic hemorrhagic transformation were noted in the bilateral temporal lobes and striatum with surrounding gliosis and numerous macrophages (Fig. 1c, Extended Data Fig. 1a) . Exuberant perivascular inflammation extending to adjacent gray matter characterized by approximately equal ratios of CD4 + and CD8 + T cells was observed (Fig. 1d) , although we noted that CD4
+ cells were present in localized patterns while CD8 + cells were diffuse and consistently present. We also observed frequent CD68
+ cells, a macrophage marker which also stains microglial cells (Extended Data Fig. 1b) . Minimal CD20 + infiltrates or immunoglobulin deposition were observed, suggesting that B cells did not constitute a major component of the inflammatory process (Extended Data Fig. 1c) . We observed similar patterns of T cell and macrophage infiltration in inflamed meninges and adjacent gray matter, including perivascular spaces (Extended Data Fig. 2 ). In contrast, brain tissue obtained from radiographically normal brain was histologically unremarkable with no inflammatory infiltrate (Extended Data Fig. 3) .
We then profiled the T cell exhaustion markers PD-1 and programmed death ligand 1 (PD-L1). PD-L1 was diffusely expressed by cells with macrophage morphology (Fig. 1e) . We observed few to no cells expressing PD-L1 in samples from patients with encephalitis of other etiologies (Supplementary Table 3 ). These samples also showed minimal to no lymphocytic infiltration, suggesting that PD-L1 expression in the brain may represent an attempt to dampen lymphocyte-derived inflammation and injury. PD-1 was expressed at lower levels by infiltrating lymphocytes and pericytes, cells which surround the capillary and venular endothelium and help maintain the blood-brain barrier (Extended Data Fig. 4) 
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. This pattern of immune cell infiltration and exhaustion markers were reminiscent of that reported in two cases of fulminant ICI-induced myocarditis 5 . We profiled other markers of immune exhaustion including CD223/LAG-3 (T cells), CD244/2B4 (natural killer (NK) cells) and CD160 (CD8 + T cells and NK cells) in the inflammatory microenvironment and histologically normal regions (Extended Data Fig. 5 ). LAG-3, and to a lesser degree CD244, were highly expressed in the inflamed region but absent in the uninflamed region. We identified CD160 + cells in both tissues, although present at a higher degree in the inflamed region. These results suggested that the infiltrating T cell population likely received negative costimulation after repeated antigen exposure.
As only formalin-fixed autopsy tissue was available, we used NanoString digital spatial profiling to analyze several regions of interest (ROIs) in the immune microenvironment (Fig. 2a,  Methods) . We selected 12 ROIs each from inflamed and adjacent unaffected tissue sections (Fig. 2b) . This analysis demonstrated a high degree of T cell and cytotoxic activation, with large increases in CD4, CD8, CD3, Ki67, PD-L1, GZMB and CD45RO in the affected region and minimal increase in the B cell markers CD19 and CD20 (Fig. 2c) . We extended this analysis across additional Atezolizumab, chemotherapy (n = 2); atezolizumab, bevacizumab (n = 2); atezolizumab, cobimetinib (n = 1); ipilimumab, crizotinib, nivolumab (n = 1); ipilimumab, bevacizumab (n = 1); ipilimumab, nivolumab, golimumab (n = 1); ipilimumab, interferon (n = 1); ipilimumab, nivolumab, cabozantinib (n = 1); ipilimumab, aldesleukin (n = 1); nivolumab, cabozantinib (n = 1); nivolumab, denosumab (n = 1); nivolumab, brentuximab (n = 1); pembrolizumab, chemotherapy (n = 1).
b Pancreatitis (n = 1), insulin-dependent type 1 diabetes, hypopituitarism (n = 2), hypophysitis (n = 2), cytokine storm (n = 1), autoimmune nephritis (n = 1) We used the following MedDRA 21.0 search term levels for our reaction criteria: encephalitis and/or encephalitis autoimmune and/or limbic encephalitis and/or meningoencephalitis and/or cerebellitis. For our substance criteria, we used pembrolizumab, atezolizumab, nivolumab, durvalumab, avelumab, ipilimumab, tremelimumab and all combinations thereof. NSCLC, non-small cell lung cancer. Letters Nature MediciNe and Ki67) in the present case (Fig. 2d) . We next asked what markers were specifically enriched on the infiltrating T cell population, selecting two CD3 + T cell-specific ROIs on the inflamed region of the brain, as well as non-ICI encephalitic cases (Fig. 2e) . While CD3 is expected to be enriched in these ROIs based on its use of fluorescently-labeled selection markers, this analysis further localized Ki67, CD45RO and GZMB specifically to T cells (Fig. 2f) . Altogether, we reasoned that activated memory T cells were likely playing an important role in the pathophysiology.
Using RNA-seq and CIBERsort analysis (see Methods), we observed several key changes in the inflamed region: (1) conversion of naïve CD4 cells to CD4 memory-activated T cell population in the inflamed tissue, (2) conversion from resting to activated mast cells, (3) a loss of memory B cells and (4) differentiation of M0 to M1/M2 macrophage phenotypes (Extended Data Fig. 6a ). As a response to anti-PD-1 therapy has been linked to type-II interferon (IFN) responses, we asked whether IFN-γ-inducible genes were also over-represented in the inflamed region. Such genes were markedly upregulated (Extended Data Fig. 6b ; Source Data Extended Data Fig. 6 ).
To quantify the clonality of these infiltrating T cells, we performed TCRβ CDR3 sequencing using the immunoSEQ and ArcherDX platforms on: (1) the inflamed and unaffected regions of the brain, (2) prior resections of the tumor-adjacent lymph node, mesentery and metastasis to the brain and (3) the recurrence scar and spleen. The inflamed section demonstrated a high T cell fraction (71% of nucleated cells, Fig. 3a ) and high degree of productive T cell clonality (0.369, Fig. 3b,c) . Notably, a single TCRβ sequence comprised 19 .6% of all infiltrating T cells (CDR3 amino acid CASSFPSGSYEQYF, Fig. 3d ), with two other high-frequency clones comprising 5.98% and 5.91% of infiltrating T cells respectively. For comparison, the most prevalent clone infiltrating the cardiac muscle of two patients with myocarditis 5 was approximately 9% (compared with 19.6% in this case of encephalitis). We detected this dominant clone at 1.08% in the spleen and 6.44% in the recurrence scar, though analyses of the TCR repertoire of additional tissues revealed mostly unique repertoires in comparison with the brain (Extended Data Fig. 7) .
We performed six-digit HLA typing (see Methods and Supplementary Table 4) on the index case to leverage existing databases of TCR-antigen specificity and provide a contextual understanding of the TCR repertoire. Bioinformatic analyses (see Methods) revealed: (1) a PSGS motif expanded in the TCR repertoire in the inflamed brain found exclusively in TCRs recognizing viral proteins and not autoimmune TCRs (Supplementary Table 5 ) and (2) TCR CDR3β sequences identical to known EBV-specific TCRs. Further query of publicly available databases (see Methods) revealed 23 further EBV-specific TCRs, including seven that exactly matched known HLA-A2-restricted EBV-specific TCRs that were previously described as specific to the epitopes GLC (BMLF1) and YVL (BRLF1) [11] [12] [13] [14] [15] [16] [17] . These sequences represented 10.9% of infiltrating T cells in the inflamed region of the brain, including the second most dominant TCR (Fig. 3e,f) . We observed these sequences at frequencies higher than those found in acute-phase infectious mononucleosis patients and in the synovial fluid of rheumatoid arthritis patients, in whom these TCRs were first detected at frequencies of 5% of CD8 + T cells 11 . While the frequency of these EBV-specific sequences fell to less than 1% of CD8 + T cells over time in acutely infected patients in those studies, we observed a distinct increase in the frequency of EBV-specific sequences in multiple tissues of the index case over time (Fig. 3g) . These sequences also occupied 16.1% of sequences detected in the spleen biopsy of this patient and 5% of the brain recurrence scar. Notably, we did not detect any previously described HLA-A2-restricted or HLA-restriction-unknown TCRs specific to MelanA epitopes (see Methods).
Given consistent findings in our earlier data suggesting a predominance of CD4 memory-activated T cells in the inflamed region, we performed dual RNA in situ analysis (using an RNA probe specific to the oligoclonal RNA sequence) and immunohistochemistry (IHC) to characterize the cells. This analysis surprisingly yielded a complete localization of CASSFPSGSYEQYF + cells to CD4
+ T cells (Fig. 3h) . Furthermore, these CD4 + cells were also GZMB + (40%), CD45RO + (55%) and Ki67 + (10-15%) ( Fig. 3i-k) . Thus, the oligoclonal cells detected by TCRβ sequencing are likely the same cells identified by digital spatial analysis and CIBERSORT, together corroborating that CD4 memory-activated T cells played a key role in this syndrome. Importantly, the second dominant TCR sequence (CASSRGQGSADTQYF), recognizing immediate-early HLA-A2-restricted epitopes GLC (BMLF1) and YVL (BRLF1), was found specifically in CD8 + T cells as expected and also colocalized with markers of activation ( Fig. 3j and Extended Data Fig. 8 ).
Given the persistently positive EBV polymerase chain reaction from multiple CSF samples and EBV-specific TCRβ sequences (reported below) identified in the brain, we performed a diagnostic RNA in situ hybridization (RNA-ISH) stain against EBV-encoded RNAs (EBER1/2). We identified rare but replicable EBER + lymphocytes in the cortex and meninges (Extended Data Fig. 9a ,b, respectively) of the affected region of the brain. EBNA1-specific RNA-ISH confirmed the presence of EBV-infected cells (Extended Data Fig. 9c,d ). Staining of a lymph node dissection anteceding pembrolizumab indicated the presence of EBER + cells, suggesting that the encephalitis did not arise from acute infection (Extended Data Fig. 9e) . Surprisingly, EBER staining of the patient's resected brain metastasis, also pre-dating immunotherapy and symptoms, identified rare melanoma cells with EBER reactivity (Extended Data Fig. 9f ). EBNA1 staining of nine additional non-immunotherapy related encephalitis cases demonstrated complete absence of EBER + lymphocytes in all cases, suggesting that EBV + lymphocyte presence is an uncommon finding in cases of encephalitis caused by other etiologies (Supplementary Table 3) . Notably, archival neural tissue from two other cases of ICI encephalitis, with substantially less robust inflammation, had negative EBER staining (Extended Data Fig. 10 ).
The molecular basis of ICI toxicity is unclear and difficult to analyze as such cases seem to arise stochastically. While these 19, 20 , early B cell changes 21 and specific intestinal microbiota 22 . We observed an extremely clonal cytotoxic CD4
+ T cell population in this sample. Such cells have central roles in autoimmunity 23 , anti-tumor immunity 24, 25 and antiviral defense 26, 27 . We cannot exclude the possibility that the clone we describe above is restricted by HLA-A2, as CD4 + T cells restricted by HLA class I and CD8 + T cells restricted by HLA class II have been described in numerous healthy and disease states [28] [29] [30] [31] . The frequency and phenotype of the CD4 + clone described above may suggest a new role for cytotoxic memory CD4 + T cells with respect to tumor control and dangerous autoreactivity as shown by others 24, 25 . Indeed, select TCRs are restricted by peptides presented on both HLA class I and class II, implying that such TCRs possess multiple specificities 32 . The presence and frequency of both CD4
+ and CD8 + cytotoxic T cell populations in the brain and tumor microenvironment merit further study in additional cancer types and in autoimmune models, particularly given that the additional cases we examined both showed marked inflammation-associated T cell infiltration of the CNS. Further studies are also needed to determine the best interventions for prevention and management of these rare but fulminant toxicities.
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Methods Index patient and autopsy data. The index patient consented to protocols that permitted de-identified research use of biospecimens, genetic testing results and clinical data (Vanderbilt IRB numbers 100178, 181685 and 030220) and his family consented to a postmortem histopathologic evaluation; cases from outside institutions were approved with institution-specific protocols. Clinical data were obtained through chart review. During the autopsy, evaluation for melanoma using standard melanoma stains (MITF, MelanA, SOX10, S100), and histopathologic evaluation of infiltrating immune cell subsets using CD3, CD20 and CD68 was performed in accordance with institutional protocols.
Additional cases of checkpoint inhibitor-associated encephalitis. Additional case 1 was seen at the University Hospital, Zurich, Switzerland and has been previously described 33 . Briefly, she was a 60-year-old (in 2012) patient with an isolated lesion in the right gyrus frontalis medius as well as bilateral pulmonary metastases. After neurosurgical resection followed by adjuvant radiotherapy (with a total of 30 Gray (Gy)) the patient was treated with ipilimumab (3 mg kg -1 intravenously) for a total of four doses. After 3 months from the last dose, the patient reported generalized tiredness, weakness and loss of appetite. Serum endocrinological work-up revealed a non-significant cortisol shift without osmolality changes, which was not specific for hypopituitarism or adrenal insufficiency. No new metastases were found in the MRI of the brain. A new positron emission tomography-computer tomography (CT) scan showed bilateral pulmonary progression. Subsequent therapy with pembrolizumab was initiated (one infusion). The patient died without any antecedent evidence of altered physical status within 2 weeks. At autopsy, gross inspection revealed a 3 cm defect in the right frontal lobe. No other lesions were seen on further sectioning. Microscopic examination was remarkable for scattered perivascular and parenchymal collections of mature lymphocytes, mostly CD8
+ T cells, in the hemispheres and brainstem. In addition, sections of brainstem showed CD68 + microglial cells, occasionally organized in loose nodules. IHC preparations for cytomegalovirus, HSV I and II, simian virus 40, toxoplasmosis and varicella zoster virus were negative. There was evidence of melanoma metastasis, even after additional sampling. A diagnosis of encephalitis was rendered based on the presence of intraparenchymal and perivascular CD8 + lymphocytes accompanied by microglial proliferation.
Additional case 2 was seen at Dana-Farber Cancer Institute in Boston, MA, USA and initially presented in 2013 with a T1a melanoma of the left lower extremity. He was followed until 2015 when he noted increased dyspnea on exertion and a CT scan showed numerous enlarged lymph nodes throughout the chest, abdomen and pelvis. The largest of these was a 7.4 × 5.3 cm 2 left pelvic sidewall node with numerous other large nodes noted. He underwent an ultrasound-guided biopsy which demonstrated metastatic melanoma. He was started on single-agent pembrolizumab and after the first dose started reporting increased tremors and leg weakness. Due to the subacute nature of these symptoms he received two more treatments with pembrolizumab with progressively worsening symptoms. He developed increased weakness and memory issues and the pembrolizumab was held and he was admitted for work-up of this. Lumbar puncture X3, MRI of the brain and spine, neurologic evaluation and extensive work-up for other causes of his symptoms was performed without an etiology. He received a short course of high-dose steroids followed by intravenous immunoglobulin and a longer steroid taper without benefit. His functional status continued to decline without a clear etiology despite these interventions and brain biopsy was performed which showed T cell inflammatory infiltrate and gliosis suspicious for pembrolizumab-related encephalopathy. He subsequently died from progressive neurologic decline.
Additional cases of encephalitis of other etiologies. Additional cases of encephalitis not associated with checkpoint inhibitor use were collected under an IRB-approved protocol to study cellular heterogeneity in normal brain and brain neoplasms (IRB no. 180238). Cases were stained with EBNA1 RNA-ISH and anti-PD-L1 IHC as detailed below. Details of the cases are listed in Supplementary  Table 3 . Positive and negative control probes were used in all cases to verify specificity and presence of intact RNA for analysis. See Reporting Summary for additional information.
Immunohistochemistry. Archival tissue from the autopsy was obtained and IHC evaluation was performed. Antibodies used were anti-CD45RO (Thermo Scientific, catalog no. MA5-11532, dilution 1:1,600), anti-GZMB (Granzyme B, Biocare, catalog no. ACI 3202 AA, prediluted), anti-Ki67 (Dako, catalog no. M7240, dilution 1:200), anti-CD4 (StatLab, catalog no. RM27-10, prediluted), anti-CD8 (StatLab, catalog no. MM39-10, prediluted), anti-PD-L1 (ThermoFisher, catalog no. PA5-28115, dilution 1:7500), anti-CD68 (Abcam, catalog no. ab125212, dilution 1:600)), anti-PD-1 (Sigma-Aldrich, HPA035981, dilution 1:75), anti-CD20 (Leica, PA0906, prediluted), anti-LAG-3 (Cell Signaling, catalog no. 15372, dilution 1:200), CD244 (Proteintech, catalog no. 16677-1-AP, dilution 1:200), CD160 (Abcam, catalog no. ab202845, dilution 1:600). The Bond Polymer Refine detection system or Envision system was used for visualization. Slides were then dehydrated, cleared and coverslipped. See Reporting Summary for additional information. situ hybridization (RNA-ISH) analysis. For RNAscope RNA-ISH (Advanced Cell Diagnostics) analysis of EBNA1, standard RNAscope manufacturer's protocols were followed using the RNAscope H 2 O 2 and protease pretreatment kit, (ACD, reference no. 322381), RNAscope Target retrieval buffer (ACD, reference no. 322000) and appropriate positive and negative RNA probes for controls. For custom BaseScope RNA-ISH (Advanced Cell Diagnostics) TCRβ analysis (ACD, reference no. 712111), standard BaseScope manufacturer's protocols were followed using BaseScope Detection Reagents, RED (ACD, reference no. 322910). Dual ISH-IHC was performed using the custom TCRβ target probe(s) followed by incubation with primary antibodies (CD4, CD8, Ki67, CD45RO and GZMB) as described above, using the Envision (Dako) system, DAB (Dako) and hematoxylin counterstain. For EBER staining, slides were placed on the Leica Bond Max IHC stainer and all steps, besides dehydration, clearing and coverslipping, were performed on the Leica Bond Max. Slides were deparaffinized, and enzyme retrieval was performed using Proteinase K (Dako, reference no. S3020) for 5 min. Slides were put through ISH hybridization with the Ready-To-Use EBER probe (Leica, reference no. ISH5687-A) for 2 h. Slides were placed in an anti-fluorescein antibody (Leica, reference no. AR0222) for 15 min. The Bond Polymer Refine detection system was used for visualization. Slides were then dehydrated, cleared and coverslipped. For dual staining, data were quantified by colocalization of the signal as a fraction of the TCR + cells, by a licensed pathologist (PIE-G).
RNA in
RNA sequencing. Total RNA quality was assessed using the 2200 TapeStation (Agilent). At least 20 ng of DNase-treated total RNA having at least 30% of the RNA fragments with a size >200 nucleotides (DV200) was used to generate RNA Access libraries (Illumina) following manufacturer's recommendations. Library quality was assessed using the 2100 Bioanalyzer (Agilent) and libraries were quantitated using KAPA Library Quantification Kits (KAPA Biosystems). Pooled libraries were subjected to 75 base pair paired-end sequencing according to the manufacturer's protocol (Illumina HiSeq3000). Bcl2fastq2 Conversion Software (Illumina) was used to generate de-multiplexed FASTQ files. Quality control (QC) for the paired-end raw sequencing reads of all samples were performed using FastQC 34 for the analysis of sequence quality, guaninecytosine (GC) content, adapter content, over-represented k-mers and duplicated reads. Sequencing reads were mapped to human reference genome GRCh38 (Release-85, Ensembl) using STAR 2.2.1 with two-pass mapping 35 . QC for read alignment and mapping was evaluated with RSeQC 36 for sequencing saturation, mapped reads clipping profile, mapped read distribution and coverage uniformity. Transcript-per-million values were calculated using RSEM 37 and used to assess the global quality and replicability of the RNA-seq data set and exported for downstream data analyses.
CIBERSORT and gene set analysis. CIBERSORT analysis was performed on RNA-seq transcript-per-million level data generated above, using both the 'relative' and 'absolute' methods available on the analysis website (https://cibersort.stanford.edu/). The CIBERSORT method used is explained in full detail elsewhere 38 . To complete this analysis, we used the LM22 data set which was carefully developed and validated in the manuscript. The genes used, along with computational methods and development/validation approach are provided as supplemental data in the original report 38 and also freely available on the CIBERSORT website. Analysis was performed as previously described 38 .
For interferon gene set analysis, the HALLMARK_INTERFERON_GAMMA_ RESPONSE (M5913; 200 genes, 177 genes in overlap/matching) signature was downloaded from the Molecular Signatures Database (http://software. broadinstitute.org/gsea/msigdb). For each gene, the log 2 (fold change) was calculated between the inflamed and unaffected region, or across additional tissues as indicated.
TCR sequencing. TCR sequencing and clonality quantification was assessed in neuropathologist-selected (by B.M.) formalin-fixed, paraffin-embedded (FFPE) samples of highly inflamed and non-inflamed brain parenchyma using survey level immunoSEQ and the Immunoverse assay, as previously described (Adaptive Biotechnologies, ArcherDX) 39, 40 . Sequencing results were evaluated using the immunoSEQ analyzer, v.3.0. Shannon entropy, a measure of sample diversity, was calculated on the clonal abundance of all productive TCR sequences in the data set. Shannon entropy was normalized by dividing Shannon entropy by the logarithm of the number of unique productive TCR sequences. This normalized entropy value was then inverted (1 − normalized entropy) to produce the clonality metric.
TCR repertoire analysis: data processing. We processed raw immunoSEQ data for downstream analysis using VDJTools 41 . We excluded clonotypes if a TRBV or TRBJ gene was not assigned or if they were non-productive. We then recalculated the frequency of each remaining productive sequence and collapsed the resulting TCR repertoire data set by CDR3 amino acid sequence (that is the counts for two clonotypes with different nucleotide sequences encoding the same CDR3 AA sequence would be summed).
TCR repertoire analysis: clonotype annotation and known antigen assignment.
We first retrieved continuous and discontinuous CDR3β motifs significantly Letters Nature MediciNe enriched at least threefold above a naïve repertoire of 200,000 unselected CD4 and CD8 T cells at a resampling depth of 10,000 using the GLIPH algorithm 17 . We then annotated each TCR repertoire for known and possible antigen specificity and pathogenic associations using the greedy VDJMatch algorithm 42 in VDJDB against each CDR3β and significant motifs from GLIPH 17 . Multiplexed protein profiles were generated with the NanoString GeoMX digital spatial profiling platform (RUO-research use only). Formalin-fixed paraffin-embedded tissue sections of 5 μm thickness were subjected to antigen retrieval (citrate buffer pH6) and stained with a cocktail of antibodies labeled with photocleavable DNA-indexing oligos (to generate quantitative protein profiles), fluorescent anti-CD3 and anti-GFAP (visualization markers) and SYTO 83 nuclear dye (ThermoFisher, S11364). Tissues were imaged by fluorescence microscopy on the GeoMX platform and ROIs were chosen for molecular profiling. ROIs were selected as circles 200 μm in diameter from inflamed or heathy tissue or by custom masking using the fluorescent CD3 signal to specifically identify T cells and a digital micromirror device to precisely control the pattern of ultraviolet illumination. ROIs were exposed to ultraviolet light (365 nm) to release oligos which were captured via microfluidics and stored in individual wells of a microtiter plate. Following collection from all ROIs, oligos were hybridized to unique fourcolor, six-spot optical barcodes and enumerated on the nCounter platform. Data were normalized to ERCC-sequence specific probes to control for technical variation in hybridization efficiency, followed by area normalization to control for ROI size and control IgG (rabbit and mouse) to normalize for background. Data were visualized by unsupervised hierarchical clustering or grouped dot plots.
Statistics. All statistics were calculated using GraphPad Prism 8 and R v.3.5. 
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Data collection
The nCounter pipeline was used to collect oligonucleotide count data from the NanoString GeoMX platform. The commercial immuneAnalyzer/immunoSEQ pipeline was used to generate TCR sequencing data from DNA for this study. Proprietary software was used to assign ASHI-accredited 4-digit resolution HLA genotypes as previously described.
Data analysis VDJTools 1.1.8 was used to process TCR sequencing data and to parse functional TCR sequences. GLIPH version 1 was used for motif enrichment analysis of TCR sequencing data. TCRex version 1 (last accessed 12 October 2018) was used to perform in silico epitope binding predictions with TCR sequencing data. McPAS-TCR and VDJDB were used to annotate TCR sequencing data for known specificities (last accessed 2 June 2019). immunoSEQ data were analyzed with immunoSEQ Analyzer 3.0.
Bcl2fastq2 v.1.8.4 was used to convert raw sequencing data to FASTQ format. QC of RNAseq data was performed using FastQC. STAR 2.2.1 with 2-pass mapping was using to align sequencing reads to GRCh38 (Ensembl, release 85). Further QC after alignment and mapping was performed using RSeQC. Transcripts per million (TPM) were calculated using RSEM. CIBERSORT (cibersort.stanford.edu) was used to characterize the immune cell composition of the RNAseq data. The HALLMARK_INTERFERON_GAMMA_RESPONSE signature from MSigDB was used to score interferon pathway activity.
All statistical testing in R was performed using the base R language, version 3.5.1. GraphPad Prism version 7 was used where listed for other statistical testing.
For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors/reviewers. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Research guidelines for submitting code & software for further information.
